Halozyme has signed a deal to purchase auto-injector specialist Antares Pharma for about $960 million, or $5.6 per share, to further expand its drug delivery offerings.
EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration...
Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2...
EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief...
EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target action date of March 28, 2022, under the Prescription Drug User Fee Act (PDUFA).
EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone.
EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver a liquid stable formulation of hydrocortisone.
We apply a tailored approach to engineering auto injectors and multi dose pens allowing patients to self-administer therapies. Our success in developing and commercializing proprietary and partnered products has been validated by the consecutive FDA approvals of seven drug-device combination products, including our proprietary product, XYOSTED® and our partners generic EpiPen® product. With the ability to supply clinical and commercial finished product in tandem with clinical, regulatory and formulation development expertise, Antares Pharma represents the preferred drug-device combination products partner.
EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. n(NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, ntoday announced that Robert F. Apple, President and Chief Executive nOfficer, is scheduled to virtually present and host investor meetings atnthe Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021.